Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
about
Metastatic disease from uveal melanoma: treatment options and future prospectsChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.The biology of uveal melanomaNRAS-mutant melanoma: current challenges and future prospectEvolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion.Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.Dual Function of Gold Nanoparticles in Synergism with Mitoxantrone and Microwave Hyperthermia Against Melanoma CellsRecent advances in uveal melanoma treatment.ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.[Malignant intraorbital tumor: Primary tumor or metastasis?].Selumetinib-based therapy in uveal melanoma patient-derived xenografts.A novel combinatorial treatment option for metastatic uveal melanoma.MEK inhibitors for the treatment of NRAS mutant melanoma
P2860
Q26738377-FE468078-7929-4307-AC13-05B37CCA5488Q26770492-F2A3A914-1976-4DC5-9F6C-5531A00F7C92Q33885560-EF9C0A8B-5905-4BE7-9054-C14E43F5F24AQ37742632-3BABFD76-3C4C-4CDD-BDA8-79122B4DB600Q38598958-63804BAD-CFAF-47A5-BFB8-ACF518C48613Q38646057-0FF0ED3D-8684-461A-A092-9F75BCD81172Q38718726-41808D2C-6498-404B-ACE4-7C308C109A60Q38798084-7D19CFF2-49C8-47F3-8841-8A7B643FAD6EQ39145837-7BFC9976-3C19-4DEA-8921-062FA2F0F518Q40251215-FB179096-193E-41A0-920B-33CF13285F19Q41609825-83F6D881-BBD4-46D0-BFE7-4308E5E3748CQ47317062-1ECB9978-31B4-4184-9D1E-CE4AC0264CD6Q47571643-CD25C762-C1CE-41BC-8230-196018DCB6E0Q47655869-C35049EF-CA00-41FA-93B7-2F76AF13B680Q53143589-BE31CBC7-413C-40FF-B264-AEDF82A41186Q55091535-232A5F3A-2AE7-4FFA-A5D7-ED5ACF64630AQ55280433-FD750D34-B6BA-48D1-9453-888AD56AAF1FQ56889985-5295F5A0-0CCA-4239-A797-CA089880B978
P2860
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Study design and rationale for ...... static uveal melanoma (SUMIT).
@ast
Study design and rationale for ...... static uveal melanoma (SUMIT).
@en
type
label
Study design and rationale for ...... static uveal melanoma (SUMIT).
@ast
Study design and rationale for ...... static uveal melanoma (SUMIT).
@en
prefLabel
Study design and rationale for ...... static uveal melanoma (SUMIT).
@ast
Study design and rationale for ...... static uveal melanoma (SUMIT).
@en
P2093
P2860
P1433
P1476
Study design and rationale for ...... static uveal melanoma (SUMIT).
@en
P2093
Gary K Schwartz
Helen Mann
Paul D Nathan
Richard D Carvajal
P2860
P2888
P356
10.1186/S12885-015-1470-Z
P407
P577
2015-06-10T00:00:00Z
P5875
P6179
1019011971